Board meeting on October 29, 2026 to consider and approve September quarter results
Bliss GVS Pharma has informed the exchanges that its Board will meet on Thursday, October 29, 2026.
By ScoutQuest · · 1 min read
- Board Meeting Date
- Thursday, October 29, 2026
- Results Period
- quarter and half year ended September 30, 2026
- Trading Window Closure
- closed from October 01, 2026, stays closed till 48 hours after the results are announced
What the company told the exchanges
Bliss GVS Pharma has informed NSE (symbol: BLISSGVS) and BSE (scrip code: 506197) that a meeting of its Board of Directors will be held on Thursday, October 29, 2026, at the registered office of the Company.
The stated purpose
The Board will consider and approve, inter alia, the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026.
Why this matters to a shareholder
- This is the regular quarterly results announcement, covering both the three-month period (July to September 2026) and the six-month period (April to September 2026).
- Results are declared separately for the standalone business and for the consolidated group, so read both if you want the full picture.
- The update only schedules the meeting; the numbers themselves will come from the company on the meeting date or after.
Trading window
- The trading window for dealing in the Company's shares was closed for all Designated Persons and their immediate relatives from October 01, 2026.
- It will remain closed till 48 hours after the Unaudited Financial Results are announced.
- This is a pre-results restriction that applies to insiders such as designated persons and their immediate relatives, not a general restriction on all investors.
What to watch for
The update sets out the date and the agenda. The actual revenue, profit and segment numbers for the September 2026 quarter and half year will be the substance for investors to judge once disclosed.
Bottom line
A routine calendar notice that fixes October 29, 2026 as the date for the company's September quarter and half-year results.
Also from Bliss GVS Pharma
Anupam Rasayan and Mates Visa acquired control; erstwhile promoters reclassified to public
14 Oct 2026
Bliss GVS Pharma Ltd: 47.95% of shares pledged
6 Oct 2026
Board approves Senior Executive ESOP 2026 and Employee ESOP 2026; options up to 26,50,000 and 47,00,000 shares
1 Oct 2026
More numbers
- Trading window remains closed till this long after results48 hours
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.